The University of North Carolina (UNC) Global HIV Clinical Trials Unit (CTU) has a well established track record of high-quality, innovative clinical research, strong scientific leadership (both in and outside the NIH HIV/AIDS Networks), and access to critically important infected and at-risk populations in the Southeastern US and in Southern Africa. Drawn from a diverse team of clinical innvestigators spanning two continents, our CTU will be led by three experienced principal investigators (Joseph Eron MD, Jeffrey Stringer MD and Mina Hosseinipour MD) and will support all 5 NIH HIV Clinical Trials Networks: Adult Therapeutic Strategies, Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations, Integrated HIV Prevention Strategies, Microbicide Strategies, and Vaccine Strategies to Prevent HIV Infection. The 5 Clinical Research Sites (CRS) will include Chapel Hill CRS led by David Wohl MD (Adult Therapeutic Strategies, Integrated Prevention, Microbicide and Vaccine), Raleigh CRS led by Kristine Patterson MD (Adult Therapeutic Strategies, Integrated Prevention, Vaccine), Greensboro CRS led by Cornelius Van Dam MD PhD (Adult Therapeutic Strategy and Integrated Prevention), Malawi CRS led by Francis Martinson MD PhD (all 5 Networks) and Zambia CRS led by Benjamin Chi MD (all 5 Networks). Supporting this leadership will be Network Science Teams, comprising global experts and site collaborators who will work to execute the network scientific agendas. The CTU has also assembled a diverse group of senior scientists and public health officials to serve on our Scientific and Strategic Advisory Group. The CTU administration incorporates a highly organized structure that will be responsive to our experienced research teams across the 5 sites and will provide ongoing evaluation to ensure optimal performance and efficiency. The CTU will be supported by state-of-the-art communications and has assembled outstanding laboratory, pharmacy, quality assurance, data management and regulatory support. With its robust administrative framework, the UNC Global HIV CTU will be uniquely positioned to provide scientific leadership and clinical trials infrastructure to advance the field of agenda of he NlAID networks.
The NIH has established collaborative HIV/AIDS Clinical Trials Networks to advance the science of HIV prevention, care, and treatment. The UNC Global Clinical Trials Unit is eager to participate in this research, by reaching populations most affecte by the epidemic in North America and Africa and by contributing key scientific leadership to drive the research agenda.
|Grinsztejn, Beatriz; Hosseinipour, Mina C; Ribaudo, Heather J et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 14:281-90|
|Lennox, Jeffrey L; Landovitz, Raphael J; Ribaudo, Heather J et al. (2014) Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161:461-71|
|Kuo, Irene; Golin, Carol E; Wang, Jing et al. (2014) Substance use patterns and factors associated with changes over time in a cohort of heterosexual women at risk for HIV acquisition in the United States. Drug Alcohol Depend 139:93-9|
|Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8|
|Castillo-Mancilla, Jose R; Cohn, Susan E; Krishnan, Supriya et al. (2014) Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV Clin Trials 15:14-26|
|Haley, Danielle F; Golin, Carol; El-Sadr, Wafaa et al. (2014) Venue-based recruitment of women at elevated risk for HIV: an HIV Prevention Trials Network study. J Womens Health (Larchmt) 23:541-51|
|Haley, Danielle F; Lucas, Jonathan; Golin, Carol E et al. (2014) Retention strategies and factors associated with missed visits among low income women at increased risk of HIV acquisition in the US (HPTN 064). AIDS Patient Care STDS 28:206-17|
|Sax, Paul E; Sypek, Alexis; Berkowitz, Bethany K et al. (2014) HIV cure strategies: how good must they be to improve on current antiretroviral therapy? PLoS One 9:e113031|
|Adimora, Adaora A; Hughes, James P; Wang, Jing et al. (2014) Characteristics of multiple and concurrent partnerships among women at high risk for HIV infection. J Acquir Immune Defic Syndr 65:99-106|
|Lindsey, Jane C; Hughes, Michael D; Violari, Avy et al. (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J 33:846-54|
Showing the most recent 10 out of 20 publications